Adial Pharmaceuticals is a clinical-stage biopharmaceutical company based in Charlottesville, VA, dedicated to developing treatments for addictions and other unmet medical needs. Their lead investigational drug candidate, AD04, is a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD) currently undergoing a pivotal Phase 3 clinical trial.
Under the leadership of CEO Cary Claiborne, Adial Pharmaceuticals is focused on advancing precision medicine approaches in substance use treatment, with a particular emphasis on addressing the challenges of AUD through innovative research and development efforts.
Generated from the website